Thasso the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Search for:

Main Navigation

english
- english
- français
- deutsch
- italiano
- español
- português
thasso
thasso post
thasso toolbox
thasso academy
thasso community
thasso: about
donations
- thasso – thank you
- Donation Confirmation

Tag: Encephalopathy

Axicabtagene Ciloleucel (Yescarta) gene therapy for diffuse large B-cell lymphoma

By Joseph Gut - thasso Posted on October 19, 2017 Posted in Gene Therapy, New Drug Approval, Personalized Medicine, Thasso Post, Theragenomic Medicine Tagged with American Food & Drug Administration (FDA), Axicabtagene Ciloleucel (Yescarta), Boxed Warning, CAR T-Cell Therapy, Cerebral Edema, Cytokine Release Syndrome (CRS), Diffuse Large B-Cell Lymphoma (DLBCL), Encephalopathy, Gene Therapy, Leukoencephalopathy, Neurologic Toxicity, Non-Hodgkin Lymphoma (NHL), Risk Evaluation and Mitigation Strategy (REMS), Thasso Post, Theragenomic Medicine

October 19, 2017 – The American Food & Drug Administration (FDA) just approved Axicabtagene Ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed …

Axicabtagene Ciloleucel (Yescarta) gene therapy for diffuse large B-cell lymphoma Read more »

Footer Menu

english
thasso
thasso post
thasso toolbox
thasso academy
thasso community
thasso: about
donations